Morgan Stanley’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-785,270
Closed -$89K – 6843
2018
Q4
$89K Sell
785,270
-70,252
-8% -$46.1K ﹤0.01% 5595
2018
Q3
$1.45M Buy
855,522
+78,062
+10% +$140K ﹤0.01% 4242
2018
Q2
$1.35M Sell
777,460
-959,709
-55% -$1.66M ﹤0.01% 4413
2018
Q1
$3.18M Buy
1,737,169
+353,123
+26% +$746K ﹤0.01% 3541
2017
Q4
$3.09M Sell
1,384,046
-609,900
-31% -$1.52M ﹤0.01% 3618
2017
Q3
$5.78M Buy
1,993,946
+132,961
+7% +$454K ﹤0.01% 2807
2017
Q2
$8.28M Buy
1,860,985
+1,046,319
+128% +$4.31M ﹤0.01% 2362
2017
Q1
$3.8M Sell
814,666
-397,574
-33% -$2.31M ﹤0.01% 3157
2016
Q4
$7.38M Sell
1,212,240
-34,307
-3% -$179K ﹤0.01% 2585
2016
Q3
$6.87M Buy
1,246,547
+733,123
+143% +$3.43M ﹤0.01% 2356
2016
Q2
$1.95M Buy
513,424
+170,751
+50% +$579K ﹤0.01% 3444
2016
Q1
$946K Sell
342,673
-80,847
-19% -$293K ﹤0.01% 3986
2015
Q4
$2.4M Buy
423,520
+27,037
+7% +$165K ﹤0.01% 3332
2015
Q3
$2.1M Sell
396,483
-65,666
-14% -$508K ﹤0.01% 3465
2015
Q2
$3.84M Sell
462,149
-370,347
-44% -$1.8M ﹤0.01% 3030
2015
Q1
$3.85M Sell
832,496
-248,286
-23% -$807K ﹤0.01% 3004
2014
Q4
$3.3M Buy
1,080,782
+199,024
+23% +$589K ﹤0.01% 3110
2014
Q3
$2.46M Sell
881,758
-79,536
-8% -$289K ﹤0.01% 3262
2014
Q2
$3.91M Buy
961,294
+130,494
+16% +$554K ﹤0.01% 2890
2014
Q1
$4.41M Buy
830,800
+61,881
+8% +$347K ﹤0.01% 2693
2013
Q4
$4.27M Sell
768,919
-121,189
-14% -$523K ﹤0.01% 2719
2013
Q3
$4.01M Sell
890,108
-28,758
-3% -$129K ﹤0.01% 2642
2013
Q2
$3.91M Buy
+918,866
New +$4.62M ﹤0.01% 2562

Other funds holding SGYP

Morgan Stanley's SGYP Position: Q1 2019 in Review

Morgan Stanley sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 785,270 shares — an estimated $89K sold.

Morgan Stanley first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $8.28M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Morgan Stanley reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • Morgan Stanley sold 785,270 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $89K.
  • Morgan Stanley first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
  • Morgan Stanley's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8.28M in Q2 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Morgan Stanley's 13F filing for Q1 2019, filed 15 May 2019.